Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea · Delayed Price · Currency is KRW 9,650.00
+500.00 (5.46%)
At close: Apr 1, 2026
Pharos iBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
124.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 300.00M | 243.00M | 426.32% |
| Dec 31, 2021 | 57.00M | -130.68M | -69.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 257.56B |
| DongKoo Bio & Pharma | 238.39B |
| Daehan Nupharm | 202.40B |
| Kyung Dong Pharmaceutical | 193.64B |
| HYUNDAI BIOLAND | 130.51B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| KOREA PHARMA | 87.60B |
| Vivozon Pharmaceutical | 66.40B |